申请人:Shacham Sharon
公开号:US20110275607A1
公开(公告)日:2011-11-10
The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).
本发明通常涉及核运输调节剂领域,例如CRM1抑制剂,更具体地涉及新的取代杂环唑类化合物,这些化合物的合成和使用以及它们的制药组合物,例如在治疗、调节和/或预防与CRM1活性相关的生理状况方面的用途,例如治疗癌症和其他肿瘤性疾病、炎症性疾病、异常组织生长和纤维化疾病,包括心肌病、肺纤维化、肝纤维化、肾小球肾炎和其他肾脏疾病,以及治疗病毒感染(急性和慢性)。